Mecasermina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mecasermina" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

2^nd place

7^th place

799^th place

22^nd place

399^th place

1,563^rd place

doi.org (Global: 2^nd place; Italian: 7^th place)

dx.doi.org

D Fintini, C Brufani e M Cappa, Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency, in Therapeutics and clinical risk management, vol. 5, n. 3, 2009, pp. 553-9, DOI:10.2147/tcrm.s6178, PMC 2724186, PMID 19707272.
Keating GM, Mecasermin, in BioDrugs, vol. 22, n. 3, 2008, pp. 177-88, DOI:10.2165/00063030-200822030-00004, PMID 18481900. URL consultato il 7 maggio 2021.
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity, in J Clin Endocrinol Metab, vol. 92, n. 3, marzo 2007, pp. 902-10, DOI:10.1210/jc.2006-1610, PMID 17192294. URL consultato il 7 maggio 2021.
Backeljauw PF, Underwood LE, Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study, in J Clin Endocrinol Metab, vol. 86, n. 4, aprile 2001, pp. 1504-10, DOI:10.1210/jcem.86.4.7381, PMID 11297575. URL consultato il 7 maggio 2021.
Mauras N, Martinez V, Rini A, Guevara-Aguirre J, Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism, in J Clin Endocrinol Metab, vol. 85, n. 9, settembre 2000, pp. 3036-42, DOI:10.1210/jcem.85.9.6772, PMID 10999782. URL consultato il 7 maggio 2021.
Mauras N, Beaufrere B, Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect, in J Clin Endocrinol Metab, vol. 80, n. 3, marzo 1995, pp. 869-74, DOI:10.1210/jcem.80.3.7533772, PMID 7533772. URL consultato il 7 maggio 2021.
Rosenbloom AL, Mecasermin (recombinant human insulin-like growth factor I), in Adv Ther, vol. 26, n. 1, gennaio 2009, pp. 40-54, DOI:10.1007/s12325-008-0136-5, PMID 19198769. URL consultato il 7 maggio 2021.
Metz KA, Assa'ad A, Lierl MB, Backeljauw P, Allergic reaction to mecasermin, in Ann Allergy Asthma Immunol, vol. 103, n. 1, luglio 2009, pp. 82-3, DOI:10.1016/S1081-1206(10)60150-0, PMID 19663134. URL consultato l'8 maggio 2021.

drugs.com (Global: 399^th place; Italian: 1,563^rd place)

Increlex, su drugs.com. URL consultato il 10 gennaio 2010.

nih.gov (Global: 4^th place; Italian: 9^th place)

ncbi.nlm.nih.gov

D Fintini, C Brufani e M Cappa, Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency, in Therapeutics and clinical risk management, vol. 5, n. 3, 2009, pp. 553-9, DOI:10.2147/tcrm.s6178, PMC 2724186, PMID 19707272.
Keating GM, Mecasermin, in BioDrugs, vol. 22, n. 3, 2008, pp. 177-88, DOI:10.2165/00063030-200822030-00004, PMID 18481900. URL consultato il 7 maggio 2021.
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity, in J Clin Endocrinol Metab, vol. 92, n. 3, marzo 2007, pp. 902-10, DOI:10.1210/jc.2006-1610, PMID 17192294. URL consultato il 7 maggio 2021.
Backeljauw PF, Underwood LE, Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study, in J Clin Endocrinol Metab, vol. 86, n. 4, aprile 2001, pp. 1504-10, DOI:10.1210/jcem.86.4.7381, PMID 11297575. URL consultato il 7 maggio 2021.
Mauras N, Martinez V, Rini A, Guevara-Aguirre J, Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism, in J Clin Endocrinol Metab, vol. 85, n. 9, settembre 2000, pp. 3036-42, DOI:10.1210/jcem.85.9.6772, PMID 10999782. URL consultato il 7 maggio 2021.
Mauras N, Beaufrere B, Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect, in J Clin Endocrinol Metab, vol. 80, n. 3, marzo 1995, pp. 869-74, DOI:10.1210/jcem.80.3.7533772, PMID 7533772. URL consultato il 7 maggio 2021.
Rosenbloom AL, Mecasermin (recombinant human insulin-like growth factor I), in Adv Ther, vol. 26, n. 1, gennaio 2009, pp. 40-54, DOI:10.1007/s12325-008-0136-5, PMID 19198769. URL consultato il 7 maggio 2021.
Metz KA, Assa'ad A, Lierl MB, Backeljauw P, Allergic reaction to mecasermin, in Ann Allergy Asthma Immunol, vol. 103, n. 1, luglio 2009, pp. 82-3, DOI:10.1016/S1081-1206(10)60150-0, PMID 19663134. URL consultato l'8 maggio 2021.

oadoi.org (Global: 799^th place; Italian: 22^nd place)

Keating GM, Mecasermin, in BioDrugs, vol. 22, n. 3, 2008, pp. 177-88, DOI:10.2165/00063030-200822030-00004, PMID 18481900. URL consultato il 7 maggio 2021.
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity, in J Clin Endocrinol Metab, vol. 92, n. 3, marzo 2007, pp. 902-10, DOI:10.1210/jc.2006-1610, PMID 17192294. URL consultato il 7 maggio 2021.
Backeljauw PF, Underwood LE, Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study, in J Clin Endocrinol Metab, vol. 86, n. 4, aprile 2001, pp. 1504-10, DOI:10.1210/jcem.86.4.7381, PMID 11297575. URL consultato il 7 maggio 2021.
Mauras N, Martinez V, Rini A, Guevara-Aguirre J, Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism, in J Clin Endocrinol Metab, vol. 85, n. 9, settembre 2000, pp. 3036-42, DOI:10.1210/jcem.85.9.6772, PMID 10999782. URL consultato il 7 maggio 2021.
Mauras N, Beaufrere B, Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect, in J Clin Endocrinol Metab, vol. 80, n. 3, marzo 1995, pp. 869-74, DOI:10.1210/jcem.80.3.7533772, PMID 7533772. URL consultato il 7 maggio 2021.
Rosenbloom AL, Mecasermin (recombinant human insulin-like growth factor I), in Adv Ther, vol. 26, n. 1, gennaio 2009, pp. 40-54, DOI:10.1007/s12325-008-0136-5, PMID 19198769. URL consultato il 7 maggio 2021.
Metz KA, Assa'ad A, Lierl MB, Backeljauw P, Allergic reaction to mecasermin, in Ann Allergy Asthma Immunol, vol. 103, n. 1, luglio 2009, pp. 82-3, DOI:10.1016/S1081-1206(10)60150-0, PMID 19663134. URL consultato l'8 maggio 2021.